Analyst Ratings For NYSE:VRX – Valeant Pharmaceuticals International (NYSE:VRX)
Today, NYSE:VRX – Valeant Pharmaceuticals International (NYSE:VRX) stock received an upgrade by Mizuho from Neutral ➝ Buy.
Some recent analyst ratings include
- 5/15/2018-Mizuho Upgrade from a “Neutral ➝ Buy” rating to a “” rating.
- 5/9/2018-BTIG Research Reiterated Rating of Hold.
Recent Insider Trading Activity For NYSE:VRX – Valeant Pharmaceuticals International (NYSE:VRX)
NYSE:VRX – Valeant Pharmaceuticals International (NYSE:VRX) has insider ownership of 11.54% and institutional ownership of 50.27%.
- On 3/13/2018 Joseph C Papa, CEO, bought 30,000 with an average share price of $16.05 per share and the total transaction amounting to $481,500.00.
- On 3/13/2018 Paul Herendeen, CFO, bought 15,000 with an average share price of $16.10 per share and the total transaction amounting to $241,500.00.
- On 3/8/2018 Schutter Richard U De, Director, bought 10,000 with an average share price of $15.34 per share and the total transaction amounting to $153,400.00.
- On 3/6/2018 John Paulson, Director, bought 7,066,629 with an average share price of $15.40 per share and the total transaction amounting to $108,826,086.60.
- On 11/16/2017 John Paulson, Director, bought 344,216 with an average share price of $14.40 per share and the total transaction amounting to $4,956,710.40.
- On 8/21/2017 Schutter Richard U De, Director, bought 10,000 with an average share price of $14.33 per share and the total transaction amounting to $143,300.00.
- On 5/11/2017 Schutter Richard U De, Director, bought 20,000 with an average share price of $13.90 per share and the total transaction amounting to $278,000.00.
Recent Trading Activity for NYSE:VRX – Valeant Pharmaceuticals International (NYSE:VRX)
Shares of NYSE:VRX – Valeant Pharmaceuticals International closed the previous trading session at 21.73 up +0.92 4.42% with 21.290000915527344 shares trading hands.